Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
148 hedge funds and large institutions have $536M invested in Momenta Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 35 closing their positions.
7% more capital invested
Capital invested by funds: $500M → $536M (+$36.2M)
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
6% less funds holding
Funds holding: 158 → 148 (-10)
23% less call options, than puts
Call options by funds: $7.93M | Put options by funds: $10.3M
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$29.5M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$10.5M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.65M |
| 4 |
Primecap Management
Pasadena,
California
|
+$6.04M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$4.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.81M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.83M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$6.03M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$4.66M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.46M |
MNTA Hedge Fund Activity: Q2 2014 in Review
148 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2014, worth a combined $536M — up 7.2% from $500M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of MNTA and 25 opened new positions — a net loss of 10 holders — while 49 trimmed existing stakes and 51 added.
The largest buyer was North Tide Capital, opening a new position worth an estimated $29.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.81M.
- 148 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2014, down from 158 in Q1 2014.
- Funds reported $536M of Momenta Pharmaceuticals, Inc. stock for Q2 2014, up 7.2% quarter-over-quarter.
- 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2014 and 35 closed out, a net change of -10 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2014 was North Tide Capital, an estimated $29.5M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q2 2014 was T. Rowe Price Associates, an estimated $7.81M sold.
Based on aggregated 13F filings for Q2 2014.